Compare ASPI & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPI | FTRE |
|---|---|---|
| Founded | 2021 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.3B |
| IPO Year | 2022 | 2023 |
| Metric | ASPI | FTRE |
|---|---|---|
| Price | $6.55 | $16.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $12.00 | ★ $14.06 |
| AVG Volume (30 Days) | ★ 5.8M | 1.1M |
| Earning Date | 04-10-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $23,849,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $68.41 | N/A |
| Revenue Next Year | $126.69 | $3.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 475.48 | 1.00 |
| 52 Week Low | $3.92 | $4.46 |
| 52 Week High | $14.49 | $18.67 |
| Indicator | ASPI | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 51.16 | 63.11 |
| Support Level | $4.84 | $15.66 |
| Resistance Level | $8.41 | $18.08 |
| Average True Range (ATR) | 0.76 | 1.09 |
| MACD | -0.16 | 0.05 |
| Stochastic Oscillator | 30.72 | 78.80 |
ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.